The initiation of GLP-1 agonists was associated with a lower risk for Alzheimer’s disease and related dementias than the initiation of DPP-4 inhibitors in patients with diabetes undergoing ...

Association driven by fewer major amputations ...

GLP-1 RAs show greater cardiovascular benefits in type 2 diabetes patients with BMI ≥25 compared to DPP-4 inhibitors. Kidney protection from GLP-1 RAs remains consistent across all BMI categories. The ...

GLP-1 drugs show a potential link to reduced epilepsy risk in people with type 2 diabetes. People taking GLP-1 drugs were 16% less likely to develop epilepsy than those on DPP-4 inhibitors.

The mechanism remains unclear, but GLP-1 users had less MACE, CV death, and all-cause death driven by fewer amputations.

Those prescribed a GLP-1 RA had a significantly increased risk for new chronic cough compared with those prescribed any non-GLP-1 RA second-line medication, DPP-4 inhibitor, or sulfonylurea in a ...

Relative to GLP-1RA and DPP-4 inhibitor use, SGLT2 inhibitor use was associated with an increased risk for erythrocytosis but not an increased risk for thrombosis in T2D. Among individuals with type 2 ...

GLP-1 RA therapy linked to significantly lower risk for epilepsy compared with DPP4-i use among adults with T2DM. (HealthDay News) — For adults with type 2 diabetes mellitus (T2DM), glucagon-like ...

Taking GLP-1 medications like Ozempic is linked to a smaller risk of developing epilepsy than taking DPP-4 inhibitors. The corresponding study was published in Neurology. "Additional randomized, ...